within Pharmacolibrary.Drugs.ATC.L;

model L01FX06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0016,
    k12             = 0.3,
    k21             = 0.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dinutuximab beta is a monoclonal chimeric (mouse/human) antibody that targets the disialoganglioside GD2 antigen highly expressed on the surface of neuroblastoma cells. It is approved for use in Europe for the treatment of high-risk neuroblastoma in pediatric patients following induction chemotherapy and achieving at least partial remission.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model as described in children with relapsed/refractory neuroblastoma; both sexes, pediatric age group. Parameters are based on published population PK model.</p><h4>References</h4><ol><li><p>Stip, MC, et al., &amp; Meyer-Wentrup, F (2023). IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. <i>Journal for immunotherapy of cancer</i> 11(7) –. DOI:<a href=&quot;https://doi.org/10.1136/jitc-2023-006948&quot;>10.1136/jitc-2023-006948</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37479484/&quot;>https://pubmed.ncbi.nlm.nih.gov/37479484</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=&quot;https://doi.org/10.4161/19420862.2015.988944&quot;>10.4161/19420862.2015.988944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25484055/&quot;>https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li><li><p>Zhang, Y, et al., &amp; Dittmann, H (2022). . <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 63(2) 205–211. DOI:<a href=&quot;https://doi.org/10.2967/jnumed.120.261854&quot;>10.2967/jnumed.120.261854</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34049985/&quot;>https://pubmed.ncbi.nlm.nih.gov/34049985</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX06;
